Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterials - Acurx Pharmaceuticals

Next Previous
Drug Profile

Research programme: antibacterials - Acurx Pharmaceuticals

Alternative Names: Antibacterial agents - Acurx Pharmaceuticals; Antibiotics - Acurx Pharmaceuticals; CCP3; Multi-drug resistant antibacterials - Acurx Pharmaceuticals

Latest Information Update: 18 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acurx Pharmaceuticals
  • Class Antibacterials; Small molecules
  • Mechanism of Action DNA polymerase III inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Skin and soft tissue infections
  • No development reported Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Streptococcal infections; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 12 Aug 2026 Acurx Pharmaceuticals has patent protection forDNA polymerase III inhibitors in Japan and Mexico
  • 15 Apr 2026 9463640 - Patent Information added
  • 30 Mar 2026 Acurx Pharma has patent protection for DNA Polymerase IIIC inhibitors including compositions-of-matter, methods of use, and pharmaceutical compositions in Korea

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top